Aislinn Antrim, MA, Assistant Managing Editor

A booster shot of the Johnson & Johnson single-shot vaccine administered 56 days after the initial shot provided 94% protection against COVID-19.

Although the advisory committee’s recommendation is not binding, the FDA will take their recommendation into consideration when making a final decision on authorization of the 50-µg booster dose.

The authorization includes strict marketing restrictions on manufacturers, including restrictions on digital, radio, and television advertising, to reduce the potential for youth exposure.

Adults 40 to 59 years of age should consult their clinician before taking aspirin, and adults 60 years of age and older should stop aspirin use for the prevention of cardiovascular disease.

The authors said stigmatization threatens societal cohesion during times of national upheaval, such as during a pandemic.

Patients receiving sacituzumab govitecan also reported lower symptomatic impact of fatigue, pain, dyspnea, and insomnia.

The existence of immunoglobulin G antibodies specifically indicates recent or prior infection and can help identify individuals with an adaptive immune response to SARS-CoV-2.

Vaccine efficacy was 93% against the Delta variant at 1 month after the 2-dose vaccine regimen, although it fell to 53% after 4 months.

The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson’s single-shot vaccine administered 56 days after the primary dose provided 94% protection against symptomatic COVID-19.

Molnupiravir reduced the risk of hospitalization or death by approximately 50% among patients with COVID-19 who received the drug.

Among 38 patients with B-cell derived malignancies who were seronegative after 2 COVID-19 vaccine doses, 55% had detectable antibodies after the third dose whereas 45% remained seronegative.

The recommendation for managing cytopenias among patients treated with tyrosine kinase inhibitors is to discontinue treatment at the onset of grade 3 or higher.

The combination of cetuximab and encorafenib resulted in a median overall survival of 8.4 months, compared to 5.4 months in the control arm among patients with colorectal cancer.

Significant reductions in mean monthly migraine days compared with placebo were seen as early as weeks 1 through 4 in the clinical trial program for atogepant.

Risk stratification for survival should not dictate treatment, but stratification for thrombosis risk should play an important role in treatment decisions.

Durvalumab in combination with oleclumab reduced the risk of non-small cell lung cancer disease progression or death by 56%, whereas patients receiving durvalumab and monalizumab had a 35% reduction.

Monthly treatment with evolocumab reduced LDL-C by a mean of 38% from baseline compared to placebo among patients ages 10 to 17 with heterozygous familial hypercholesterolemia.

Policy makers should consider structural incentives to improve generic drug access, investigators say.

Co-administration of COVID-19 vaccines and flu vaccines is also available.

The prostate-specific membrane antigen-targeted positron emission tomography imaging technique will be part of the National Comprehensive Cancer Network guidelines beginning in 2022.

The COVID-19 booster doses are to be administered at least 6 months after completion of the primary 2-dose series and are the same formulation and dosage strength as the original doses.

Remdesivir demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19-related hospitalization or all-cause death by day 28.

Patients with triple-negative breast cancer who received sacituzumab govitecan had a median progression-free survival of 4.6 months compared to 2.3 months with chemotherapy.

Trial results showed a 24% confirmed objective response rate with a median duration of response of 8.3 months among patients with cervical cancer who received tisotumab vedotin-tftv.

Relatlimab is the first LAG-3-blocking antibody to demonstrate a clinical benefit for patients with melanoma in phase 3 data.

The results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of age, with results in children under 5 years of age expected as soon as later this year.

The panel did, however, vote to recommend the booster shots to adults over 65 years of age and those at high risk of severe COVID-19.

Strong immune memory lasted in all age groups tested after receiving the Moderna vaccine, including individuals over 70 years of age who are especially vulnerable to COVID-19.

Clinical trial results found a 30% reduction in the risk of death and a 2.3-month extension in median overall survival among patients with advanced or metastatic esophageal squamous cell carcinoma treated with tislelizumab.

Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.